Eric Joseph
Stock Analyst at JP Morgan
(1.25)
# 3,554
Out of 4,944 analysts
134
Total ratings
34.48%
Success rate
-12.41%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $40.74 | +57.09% | 4 | Jun 3, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.81 | - | 5 | May 20, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $45 → $44 | $3.09 | +1,323.95% | 3 | May 9, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $8.85 | -20.90% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $48.16 | +39.12% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.35 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.61 | - | 4 | Feb 10, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $31 → $30 | $10.57 | +183.82% | 7 | Jan 29, 2025 | |
| IGMS IGM Biosciences | Upgrades: Neutral | n/a | $1.27 | - | 8 | Jan 13, 2025 | |
| VIR Vir Biotechnology | Maintains: Neutral | $10 → $14 | $4.57 | +206.35% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $36.09 | +96.76% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $43 | $27.87 | +54.29% | 4 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $11.71 | +224.51% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $1.44 | +1,497.22% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $8.76 | +94.06% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $3.42 | +514.04% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $48 | $17.52 | +173.97% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $7.60 | +31.58% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.08 | - | 4 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.72 | +772.09% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.33 | +158.06% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $10 | $5.70 | +75.44% | 2 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $4.43 | +148.31% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $41 | $48.33 | -15.17% | 2 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $10.71 | +833.71% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $0.53 | +837.73% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.50 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $6.49 | +69.49% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.29 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $4.45 | +2,596.63% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $7.50 | +3,900.00% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.27 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.84 | +389.13% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.30 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.77 | +1,416.25% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $1.09 | +1,098.16% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.54 | +1,938.55% | 3 | Nov 14, 2018 |
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $40.74
Upside: +57.09%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.81
Upside: -
Rocket Pharmaceuticals
May 9, 2025
Maintains: Overweight
Price Target: $45 → $44
Current: $3.09
Upside: +1,323.95%
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $8.85
Upside: -20.90%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $48.16
Upside: +39.12%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.61
Upside: -
Nurix Therapeutics
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $10.57
Upside: +183.82%
IGM Biosciences
Jan 13, 2025
Upgrades: Neutral
Price Target: n/a
Current: $1.27
Upside: -
Vir Biotechnology
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $4.57
Upside: +206.35%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $36.09
Upside: +96.76%
Nov 25, 2024
Maintains: Overweight
Price Target: $30 → $43
Current: $27.87
Upside: +54.29%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $11.71
Upside: +224.51%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $1.44
Upside: +1,497.22%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $8.76
Upside: +94.06%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $3.42
Upside: +514.04%
Aug 7, 2024
Maintains: Overweight
Price Target: $45 → $48
Current: $17.52
Upside: +173.97%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $7.60
Upside: +31.58%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.08
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.72
Upside: +772.09%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.33
Upside: +158.06%
Nov 13, 2023
Maintains: Neutral
Price Target: $11 → $10
Current: $5.70
Upside: +75.44%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $4.43
Upside: +148.31%
Oct 11, 2023
Maintains: Overweight
Price Target: $62 → $41
Current: $48.33
Upside: -15.17%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $10.71
Upside: +833.71%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $0.53
Upside: +837.73%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $3.50
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $6.49
Upside: +69.49%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $10.29
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $4.45
Upside: +2,596.63%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $7.50
Upside: +3,900.00%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $4.27
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.84
Upside: +389.13%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.30
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.77
Upside: +1,416.25%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $1.09
Upside: +1,098.16%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.54
Upside: +1,938.55%